/ /

  • linkedin
  • Increase Font
  • Sharebar

    6 things you missed at Vision Expo West 2017


    MacuLogix creates guidelines for AMD treatment

    Las Vegas—MacuLogix has created guidelines for better diagnosing and treatment of age-related macular degeneration (AMD).

    According to a recent study of 1288 eyes (644 adults),1 one of four eyes studied was not diagnosed with AMD during the dilated fundus examination, despite these eyes having macular characteristics indicative of AMD in the fundus photos.

    Approximately three-fourths of the 320 undiagnosed eyes had 10 or more small drusen (249 [77.8 percent]) and/or intermediate drusen (250 [78.1 percent]). However, 30 percent of undiagnosed eyes had large drusen.

    The prevalence of undiagnosed AMD in the study did not differ based on type of eyecare provider, ophthalmologist or optometrist.

    According to MacuLogix, AMD is overlooked by practitioners based on the absence of structural findings on fundus photography and OCT—fundus and OCT look only at structure. Plus, by the time photoreceptor ellipsoid layer thinning is visible on OCT, macular function may be significantly impaired.

    Impaired dark adaptation identifies subclinical AMD at least three years before it can be seen with imaging, optical coherence tomography (OCT), or clinical exam.2

    The company has created “Practical Guidelines for the Treatment of Nonexudative AMD” to simplify AMD classification and define appropriate treatment for all stages of AMD.

    Earlier detection allows for earlier treatment, such as:

    • Prescribe smoking cessation programs

    • Prescribe nutritional supplementation

    • Discuss lifestyle modifications with respect to diet and exercise

    • Systemic disease management

    • Prescribe blue light protection

    • Prescribe UVA and UVB sunglasses protection for outdoors

    The guidelines were created by MacuLogix’s clinical advisory committee:

    • Jeffry Gerson, OD, FAAO; Chair

    • Glenn Corbin, OD

    • Steve Ferrucci, OD, FAAO

    • Paul Karpecki, OD, FAAO

    • Gary Kirman, OD

    • Kim Reed, OD, FAAO

    • Laurie Sorrenson, OD, FAAO

    MacuLogix manufactures AdaptDx dark adaptometer.



    1.Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G Jr, Owsley C. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017 Jun 1;135(6):570-575.

    2.Owsley C, McGwin G, Clark ME, Jackson GR, Callahan MA, Kline LB, Witherspoon CD, Curcio CA. Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration. Ophthalmology. 2016;123(2):344-351.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V